Skip to main content
. Author manuscript; available in PMC: 2025 Jul 1.
Published in final edited form as: J Chromatogr B Analyt Technol Biomed Life Sci. 2024 May 25;1241:124164. doi: 10.1016/j.jchromb.2024.124164

Table 5.

Stability studies

Compound Nominal concentration (ng/mL) Freeze/Thaw between - 80°C and RT Autosampler at 10°C Benchtop at RT Long-term stability
1 F/T 2 F/T 3 F/T 24h 72h 4h 72 days
Bictegravir 0.15 103.9 (4.5) 97.6 (13.2) 89.0 (4.3) 86.4 (2.2) 91.7 (8.4) 92.4 (4.1) 104.5 (6.4)
40 91.3 (1.0) 105.0 (2.6) 109.5 (1.0) 105.7 (2.7) 112.4 (2.4) 92.0 (2.1) 101.7 (8.5)
Cabotegravir 0.15 105.8 (6.5) 93.8 (7.7) 91.5 (2.1) 86.4 (2.3) 107.7 (2.1) 90.6 (4.4) 96.6 (4.4)
40 93.2 (1.0) 110.3 (3.1) 107.1 (2.5) 104.1 (3.5) 101.1 (3.0) 85.3 (1.4) 113.3 (3.9)
Dolutegravir 0.15 106.2 (6.7) 100.6 (9.3) 93.3 (1.7) 87.9 (2.1) 106.0 (5.5) 92.9 (6.5) 104.4 (5.7)
40 95.2 (1.0) 108.9 (2.9) 114.5 (1.4) 109.6 (0.9) 113.6 (1.9) 88.8 (2.6) 104.8 (9.0)
Doravirine 0.15 104.4 (0.7) 91.9 (7.2) 99.6 (11.4) 85.5 (4.7) 93.5 (5.5) 100.2 (6.4) 100.4 (6.3)
40 95.2 (1.8) 108.4 (3.6) 107.8 (3.8) 106.8 (1.9) 108.3 (1.0) 93.6 (3.0) 99.8 (1.7)
Raltegravir 0.15 111.4 (5.3) 94.0 (4.8) 94.8 (5.0) 94.7 (5.5) 108.9 (3.0) 102.2 (1.4) 111.4 (5.4)
40 100.0 (1.5) 109.3 (3.4) 112.5 (3.5) 103.0 (2.5) 106.8 (0.6) 87.9 (2.2) 109.2 (7.6)

Data are mean percent recoveries (CV%). N=3 for each stability study.